Vesicare (solifenacin) / Astellas - LARVOL DELTA

Peroneal electric transcutaneous neuromodulation versus solifenacin in the treatment of the overactive bladder wet. (PubMed, Cent European J Urol) - "Both treatments led to significant and similar improvements in all bladder diary variables, OAB V8 score, and QoL. The results of this secondary analysis confirm that peroneal eTNM® has significantly better safety profile and comparable efficacy versus solifenacin in the subgroup of incontinent OAB patients."

Journal • Overactive Bladder

Deprescribing dRrugs for Overactive Bladder in General Practice (DROP) (clinicaltrials.gov) - P=N/A | N=72 | Active, not recruiting | Sponsor: Anne Estrup Olesen | Recruiting ➔ Active, not recruiting

Enrollment closed • Overactive Bladder

Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker (clinicaltrials.gov) - P=N/A | N=180 | Completed | Sponsor: Xing Liu | Recruiting ➔ Completed

Biomarker • Trial completion • Overactive Bladder • Pediatrics

Green HPLC-Fluorescence Method for Tamsulosin and Solifenacin in Dosage Forms Optimized by Box-Behnken Design. (PubMed, Luminescence) - "The proposed method was the only method used to assess the combined tablets content uniformity. Two greenness evaluation tools, GAPI and AGREE, were used to assess the greenness of the proposed HPLC method and the results showed a remarkable compliance with the green chemistry principles."

Journal

Sertraline-Induced Urine Incontinence. (PubMed, Eur J Case Rep Intern Med) - "Sertraline can rarely cause urinary incontinence, with symptoms showing a dose-response relationship that improves after dose reduction.Recognition and management of this adverse effect (through dose adjustment, switching or adjunctive therapy) allows clinicians to maintain psychiatric remission while minimising distressing urinary symptoms."

Journal • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry • Urinary Incontinence • Urology

Persistence of Anticholinergic Agents in Patients With Overactive Bladder: A Cohort Study From the French National Health Insurance Claim Database (SNDS) (ISPOR-EU 2025) - "Solifenacin was the most prescribed at initiation (41.4%), followed by fesoterodine (38.4%). This study reveals limited persistence with ACH in the management of OAB in France. Most patients discontinued after a single delivery and remained without OAB treatment after 1-year of follow-up. These results highlight the need for strategies addressing treatment optimization and maintaining treatment adherence."

Claims database • Clinical • Reimbursement • US reimbursement • Cardiovascular • Hypertension • Overactive Bladder

Evaluation of the Potential Inhibitory Effects of Medications for Detrusor Overactivity on Platelet-Activating Factor (PAF)-Induced Mechanical Activity in Guinea Pig Bladder Smooth Muscle. (PubMed, Biol Pharm Bull) - "Ten clinically used DO drugs-oxybutynin, tolterodine, fesoterodine, propiverine, propantheline, solifenacin, imidafenacin, flavoxate, urapidil, and clenbuterol-were tested at a concentration of 10 μM, exceeding typical therapeutic plasma levels. Furthermore, oxybutynin (10 μM) also decreased 60 mM KCl-induced contractions by a similar extent and nearly abolished acetylcholine (ACh, 10 μM)-induced contractions. These findings suggest that oxybutynin suppresses PAF-induced UBSM hyperactivity through a mechanism distinct from its anticholinergic effect, likely mediated by blockade of voltage-dependent Ca2+ channels (VDCCs)."

Journal • Overactive Bladder

Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting. (PubMed, Pharmaceuticals (Basel)) - "We designed this study to assess persistence, adherence, and patient satisfaction with FDCs recently introduced to the Polish pharmaceutical market, which contain tamsulosin (an α1-adrenergic receptor antagonist) in combination with solifenacin (a muscarinic receptor antagonist) or dutasteride (a 5-α reductase inhibitor). 2. The use of FDCs increases short-term satisfaction and persistence with therapy, with a mild effect on adherence."

Journal • Benign Prostatic Hyperplasia

Overactive bladder medications and risk of emergency hospital admissions with delirium in adults without dementia: self-controlled case series. (PubMed, Age Ageing) - "We observed increased hospital admission rates with delirium for adults without dementia whilst prescribed OAB anticholinergics, but not whilst prescribed mirabegron. Delirium risk remained raised for longer for men and was greater in older men. Alternative management options for OAB in older people should be considered before prescribing anticholinergic medications."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Overactive Bladder

Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE (clinicaltrials.gov) - P3 | N=120 | Recruiting | Sponsor: Mansoura University

Monotherapy • New P3 trial • Urinary Incontinence

Long-term clinical efficacy and cognitive impact of medications for overactive bladder related to the central nervous system. (PubMed, Int Urol Nephrol) - "OAB medication efficacy was comparable across medication types, but tolerability varied significantly, with the dementia, PD and solifenacin groups showing higher discontinuation rates. Cognitive impairment significantly influenced treatment outcomes, underscoring the need for tailored therapeutic strategies and regular cognitive assessments to optimise treatment effectiveness and maintain quality of life in patients with CNS-related OAB."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Movement Disorders • Overactive Bladder • Parkinson's Disease

Combination treatment of mirabegron and solifenacin versus solifenacin monotherapy in female patients with overactive bladder - A comparative study on effectiveness, safety, symptoms and quality of life and treatment adherence. (PubMed, Urologia) - "When compared to solifenacin 5 mg monotherapy, combination therapy with solifenacin/mirabegron markedly improved OABSS, micturition frequency, and urgency. When compared to monotherapy, all combinations were well tolerated and showed no significant extra safety concerns."

HEOR • Journal • Monotherapy • Constipation • Gastroenterology • Gastrointestinal Disorder • Overactive Bladder

Comparative efficacy of solifenacin and tamsulosin in alleviating stent-related symptoms: A systematic review and meta-analysis. (PubMed, Narra J) - "No significant differences were found between tamsulosin and solifenacin in terms of QoL (MD: 0.12; 95%CI: -0.01-0.26; p=0.070) and VAS (MD: 0.25; 95%CI: -0.95-1.44; p=0.690). In conclusion, solifenacin was more effective than tamsulosin in reducing stent-related symptoms, and the combination of tamsulosin and solifenacin was superior to either monotherapy in alleviating stent-related symptoms."

Journal • Retrospective data • Review • Urology

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms (clinicaltrials.gov) - P3 | N=189 | Recruiting | Sponsor: Bir Hospital | Not yet recruiting ➔ Recruiting

Enrollment open

Novel spectrophotometric approaches for analysis of solifenacin and silodosin in pharmaceutical preparations, human plasma, and environmental water samples: assessment of the methods' greenness and practicality. (PubMed, Anal Bioanal Chem) - "Method greenness and practicality were critically evaluated using the GAPI, AGREE, and the recently introduced CACI tool, all confirming the exceptional eco-friendliness and economic viability of the approaches. Full compliance with ICH Q2(R2) guidelines further affirms their validity for routine quality control and environmental monitoring."

Journal • Overactive Bladder

Investigating the Influence of Mucus Layer, Bile Acids, and Pharmaceutical Excipients on the Intestinal Permeability of Solifenacin Using PermeaPadTM Plate. (PubMed, J Pharm Sci) - "The study concludes that PPP is a viable alternative to cell-based methods for evaluating drug permeability. This work provides insights into the mechanisms of drug permeability, which is crucial for drug development."

Journal

Central Composite Design Assisted Spectrofluorimetric Determination of Solifenacin via Quenching of Acid Red 51: Application in Pharmaceutical Formulations and Plasma. (PubMed, Luminescence) - "Under optimized conditions (acetate buffer pH 4.2, 1.1 mL buffer volume, 1.1 mL AR51 solution), the method demonstrated linearity in the concentration range of 0.2 to 44 μg/mL with detection and quantification limits of 0.0554 and 0.1678 μg/mL, respectively. The developed sensor was successfully applied for SLF determination in pharmaceutical formulations and human plasma samples with recovery rates of 99.77% and 99.01%, respectively, offering advantages over conventional methods by operating at longer wavelengths, thereby minimizing interference from endogenous fluorophores."

Journal

The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial (clinicaltrials.gov) - P3 | N=220 | Not yet recruiting | Sponsor: Far Eastern Memorial Hospital

New P3 trial • Overactive Bladder

Antimuscarinics for burn patients: Helpful or harmful for sensation recovery? (PubMed, Burns) - "Burn patients on antimuscarinic therapy were more likely to develop paresthesia, possibly indicating nerve regeneration. While this may reflect sensory recovery, it could also lead to abnormal or painful sensations that negatively impact quality of life. Further research is needed to assess functional outcomes."

Journal • Diabetes • Metabolic Disorders • Overactive Bladder • Pain • Thermal Injury

Comparing Tamsulosin and Solifenacin for Relieving Double J Stent Symptoms: Using the USSQ. (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: Liaquat National Hospital & Medical College

New P4 trial

Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease: A Randomized Noninferiority Trial. (PubMed, JAMA Neurol) - P3 | "To assess the noninferiority of behavioral compared with solifenacin drug therapy for OAB symptoms in persons with PD...These findings may inform clinical guidelines for urinary symptoms in PD to consider behavioral therapy as an initial treatment option. ClinicalTrials.gov Identifier: NCT03149809."

Head-to-Head • Journal • CNS Disorders • Movement Disorders • Overactive Bladder • Parkinson's Disease • Xerostomia

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry): Protocol for an Open-Label Prospective Randomized Trial. (PubMed, JMIR Res Protoc) - P4 | "The results are expected to influence the withdrawal strategy of pharmacological treatment with solifenacin or mirabegron in children with daytime urinary incontinence."

Clinical protocol • Journal • Urinary Incontinence • Urology

Can Stem Cell Therapy Revolutionize the Treatment of Overactive Bladder? A Systematic Review of Current and Future Potential (UAA 2025) - "Compared to solifenacin, one of the current treatments for OAB that works by blocking muscarinic receptors, MSCs showed greater effects on bladder contractility and tissue recovery.Stem cell therapy offers regenerative benefits that address the root causes of OAB, surpassing current symptom-based treatments. Stem cell therapy offers regenerative benefits that address the root causes of OAB, surpassing current symptom-based treatments. Preclinical findings are consistent and promising, and early clinical data suggest potential for meaningful symptom relief. Further controlled human trials are essential to establish safety, efficacy, and long-term outcomes."

Review • Fibrosis • Immunology • Inflammation • Overactive Bladder • Urology • NES • NGF • POU5F1 • TNFA

Pharmacological treatment of pediatric nocturnal enuresis: a systematic review and network meta-analysis. (PubMed, Pediatr Nephrol) - "Combination therapy may be superior to monotherapy in NE management. The most frequently used combination therapy is desmopressin plus anticholinergic agents. All drugs seemed to be safe."

Journal • Retrospective data • Review • Pediatrics • Urinary Incontinence

Drug-induced xerostomia and hyposalivation in patients with overactive bladder: a prospective open-label observational study comparing antimuscarinics and β3-adrenoceptor agonists. (PubMed, Sci Rep) - "This study evaluated subjective and objective oral dryness in 101 patients with overactive bladder (OAB) receiving solifenacin (5 or 10 mg) or mirabegron (50 mg). These findings underscore the need for collaboration among urologists, dentists, and otolaryngologists to identify high-risk individuals early and implement preventive strategies. Adjusting OAB pharmacotherapy regimens may help optimize treatment efficacy while minimizing xerostomia's detrimental impact on oral health and patient quality of life."

Clinical • Journal • Observational data • Cardiovascular • Dental Disorders • Hypertension • Otorhinolaryngology • Overactive Bladder • Xerostomia